secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001558370-25-008294
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus BioSciences renames to Coherus Oncology, sharpens focus on cancer immunotherapy
--------------------------------------------------------------------------------

- Name change to Coherus Oncology, Inc. effective May 29, 2025; stock ticker CHRS unchanged.
- Company now exclusively focused on proprietary immuno-oncology medicines; pipeline includes LOQTORZI, CHS-114, and casdozokitug.
- LOQTORZI is a next-gen PD-1 inhibitor approved for nasopharyngeal carcinoma; CHS-114 is a CCR8 antibody in Phase 1b.
- Casdozokitug, an IL-27 antagonist, is in a randomized Phase 2 study for first-line advanced metastatic HCC.
- Board and scientific advisors include leaders from Cancer Research Institute, MSKCC, and HHMI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025008294/0001558370-25-008294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025008294/chrs-20250529x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-008294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer